Eng Hseon Tay

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years

Darron R. Brown, Susanne K. Kjær, Kristján Sigurðsson et al. · The Journal of Infectious Diseases · 2009 · 627 citations · Full text

Medicine, Oncology, Pathology +17

Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women

Nubia Muñóz, Susanne K. Kjær, Kristján Sigurðsson et al. · JNCI Journal of the National Cancer Institute · 2010 · 564 citations · Full text

Medicine, Gynecology, Infectious Diseases +16

A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions

Susanne K. Kjær, Kristján Sigurðsson, Ole‐Erik Iversen et al. · Cancer Prevention Research · 2009 · 328 citations · Full text

Medicine, Gynecology, Preventive Medicine +17

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16–26 Years

Cosette M. Wheeler, Susanne K. Kjær, Kristján Sigurðsson et al. · The Journal of Infectious Diseases · 2009 · 242 citations · Full text

Medicine, Infectious Diseases, Preventive Medicine +17

Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection

Sven-Eric Olsson, Susanne K. Kjær, Kristján Sigurðsson et al. · Human Vaccines · 2009 · 218 citations · Full text

Medicine, Immunology, Preventive Medicine +17